成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. NF-κB Autophagy Apoptosis Anti-infection
  2. NF-κB Autophagy Apoptosis Ferroptosis Bacterial Antibiotic
  3. Sulfasalazine

Sulfasalazine  (Synonyms: 柳氮磺吡啶; NSC 667219)

目錄號(hào): HY-14655 純度: 98.75%
COA 產(chǎn)品使用指南 技術(shù)支持

Sulfasalazine (NSC 667219) 常用于類(lèi)風(fēng)濕關(guān)節(jié)炎和潰瘍性結(jié)腸炎的相關(guān)研究。Sulfasalazine 可抑制 NF-κB 的活性。Sulfasalazine 是 type 1 的鐵死亡 (ferroptosis) 誘導(dǎo)劑。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Sulfasalazine Chemical Structure

Sulfasalazine Chemical Structure

CAS No. : 599-79-1

1.  客戶(hù)無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶(hù)。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥500
In-stock
500 mg ¥400
In-stock
1 g ¥500
In-stock
5 g ¥800
In-stock
10 g   詢(xún)價(jià)  
50 g   詢(xún)價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Sulfasalazine:

MCE 顧客使用本產(chǎn)品發(fā)表的 39 篇科研文獻(xiàn)

WB

    Sulfasalazine purchased from MCE. Usage Cited in: Mol Ther. 2021 Mar 17;S1525-0016(21)00142-8.  [Abstract]

    PD-L1 expression is significantly increased after Sulfasalazine (SAS) treatment at both the protein and mRNA levels.

    Sulfasalazine purchased from MCE. Usage Cited in: Cell Res. 2018 Dec;28(12):1171-1185.  [Abstract]

    Melanoma A375 cells are treated with SSZ (Sulfasalazine, 125?μM) with or without FeSO4 (100?μM) for 6?h to detect the ROS level or 24?h to assess the pyroptotic features (including morphology, GSDME cleavage, and LDH release), unless specifically defined.
    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer[1][2][3][4].

    IC50 & Target[1]

    RelA

     

    Autophagy

     

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    HEK293 IC50
    0.56 μM
    Compound: Sulfasalazine
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
    [PMID: 22541068]
    HEK293 IC50
    12 μM
    Compound: Sulfasalazine
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
    [PMID: 22541068]
    HEK293 IC50
    3 μM
    Compound: Sulfasalazine
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
    [PMID: 22541068]
    HepG2 IC50
    0.9 μM
    Compound: SFZ
    Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
    Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
    [PMID: 21870831]
    HepG2 IC50
    0.9 μM
    Compound: Sulfasalazine
    Inhibition of TNF-alpha-induced NF-kappaB transcriptional activation in human HepG2 cells preincubated for 1 hr followed by TNF-alpha challenge measured after 1 hr by luciferase reporter gene assay
    Inhibition of TNF-alpha-induced NF-kappaB transcriptional activation in human HepG2 cells preincubated for 1 hr followed by TNF-alpha challenge measured after 1 hr by luciferase reporter gene assay
    [PMID: 24314396]
    HepG2 IC50
    0.9 μM
    Compound: SFZ
    Inhibition of NF-kappaB expressed in human HepG2 cells assessed as inhibition of TNFalpha-induced luciferase activity preincubated for 1 hr followed by TNFalpha challenge measured after 1 hr by reporter gene assay
    Inhibition of NF-kappaB expressed in human HepG2 cells assessed as inhibition of TNFalpha-induced luciferase activity preincubated for 1 hr followed by TNFalpha challenge measured after 1 hr by reporter gene assay
    [PMID: 23031596]
    HepG2 IC50
    0.9 μM
    Compound: Sulfasalazine
    Inhibition of TNFalpha-induced NFkappaB transcriptional activity in human HepG2 cells pretreated for 1 hr before TNFalpha challenge by luciferase reporter gene analysis
    Inhibition of TNFalpha-induced NFkappaB transcriptional activity in human HepG2 cells pretreated for 1 hr before TNFalpha challenge by luciferase reporter gene analysis
    [PMID: 22381047]
    HepG2 IC50
    0.9 μM
    Compound: Sulfasalazine
    Inhibition of NF-kappaB activation expressed in TNFalpha-stimulated human HepG2 cells co-transfected with PPRE-Luc plasmid pretreated for 1 hr before TNFalpha challenge measured after 24 hrs by luciferase reporter gene assay
    Inhibition of NF-kappaB activation expressed in TNFalpha-stimulated human HepG2 cells co-transfected with PPRE-Luc plasmid pretreated for 1 hr before TNFalpha challenge measured after 24 hrs by luciferase reporter gene assay
    [PMID: 21889336]
    T-cell IC50
    > 10 μM
    Compound: Salazosulfapyridine
    Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells
    Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells
    [PMID: 11229767]
    U2OS IC50
    9.6 μM
    Compound: Sulfasalazine
    Inhibition of HA-tagged human NTCP expressed in human U2OS cells assessed as reduction in [14C]taurocholate uptake preincubated for 10 mins followed by [14C] taurocholate addition and further incubation for 10 mins by scintillation counting method
    Inhibition of HA-tagged human NTCP expressed in human U2OS cells assessed as reduction in [14C]taurocholate uptake preincubated for 10 mins followed by [14C] taurocholate addition and further incubation for 10 mins by scintillation counting method
    [PMID: 31439379]
    U-87MG ATCC IC50
    30 μM
    Compound: 2
    Inhibition of xc-cystine-glutamate antiporter-mediated cystine uptake in human U87 cells using L-[14C]cystine as substrate after 15 mins by liquid scintillation counting
    Inhibition of xc-cystine-glutamate antiporter-mediated cystine uptake in human U87 cells using L-[14C]cystine as substrate after 15 mins by liquid scintillation counting
    [PMID: 21889337]
    體外研究
    (In Vitro)

    用柳氮磺吡啶處理 SW620 結(jié)腸細(xì)胞可抑制 TNFα、LPS 或佛波醇酯誘導(dǎo)的 NFκB 活化。柳氮磺吡啶在微摩爾至毫摩爾濃度下可抑制 NFκB 依賴(lài)性轉(zhuǎn)錄。柳氮磺吡啶通過(guò)抑制 IκBα 降解來(lái)阻止 TNFα 誘導(dǎo)的 NFκB 核轉(zhuǎn)位[1]。僅用 5 mM 柳氮磺吡啶預(yù)孵育可顯著增加所有促炎細(xì)胞因子的基礎(chǔ) mRNA 表達(dá),IL-6 mRNA 水平與載體對(duì)照相比增加 80 倍[2]。消化后,柳氮磺吡啶被結(jié)腸細(xì)菌裂解為磺胺吡啶和 5-氨基水楊酸,據(jù)報(bào)道后者也會(huì)抑制 NF-κB 活性[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內(nèi)研究
    (In Vivo)

    與未經(jīng)治療的對(duì)照組相比,Sulfasalazine (0.25 mM) 能夠抑制超過(guò) 60% 的膠質(zhì)瘤生長(zhǎng)[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    398.39

    Formula

    C18H14N4O5S

    CAS 號(hào)
    性狀

    固體

    顏色

    Light yellow to orange

    中文名稱(chēng)

    柳氮磺吡啶;水揚(yáng)酸偶氮磺胺毗嚨

    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.

    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn): 

    NH4OH 中的溶解度 : 150 mg/mL (376.52 mM; 超聲助溶; 堿性條件溶解 ( NH4OH 調(diào)節(jié),pH≈9))

    1 M NaOH 中的溶解度 : ≥ 100 mg/mL (251.01 mM)

    DMSO 中的溶解度 : 80 mg/mL (200.81 mM; 超聲加熱助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開(kāi)封的 DMSO)

    * "≥" means soluble, but saturation unknown.

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.5101 mL 12.5505 mL 25.1010 mL
    5 mM 0.5020 mL 2.5101 mL 5.0202 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
    儲(chǔ)備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn):

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.28 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL

      生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (6.28 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

      2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。

    以下溶解方案,請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配,在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比; 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶。

    • 方案 一

      請(qǐng)依序添加每種溶劑: 50% PEG300    50% Saline

      Solubility: 10 mg/mL (25.10 mM); 懸濁液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    由于實(shí)驗(yàn)過(guò)程有損耗,建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
    方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購(gòu)。 Tween 80,均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度,以下方案僅供參考,如有需要,請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
    連續(xù)給藥周期超過(guò)半月以上,請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.04%

    參考文獻(xiàn)
    Kinase Assay

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Sulfasalazine is dissolved in culture medium. SW620 cells are grown in Dulbecco’s modified Eagle medium, supplemented with 10% heat-inactivated FCS, 2 mmol/liter glutamine, and 1% (wt/vol) penicillin/streptomycin. SW620 cells are transfected with the 3xIgkBLuc reporter construct. After 18 h, cells are incubated with either medium alone or with sulfasalazine (0.1, 0.2, 0.5, 1, 2, 5 mM) before stimulation with TNFα, LPS, or PMA. Luciferase assay is performed[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3]

    Mice: Sulfasalazine is dissolved in 0.1 M NaOH, and then neutralized by titrating with 0.1 M HCl. U-87MG glioma cells are implanted into the cranium of a SCID mouse. After 7 days, animals are randomized into three groups of five animals each. One group receives 1 mL i.p. saline injections twice daily for 3 weeks. The two test groups receives 8 mg of sulfasalazine in 1 mL saline twice daily for 3 weeks. Tumor growth and animal health were monitored. After perfusion with 4% paraformaldehyde, mouse brains were collected, rinsed, and placed in 30% sucrose[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO / 1 M NaOH / NH4OH 1 mM 2.5101 mL 12.5505 mL 25.1010 mL 62.7526 mL
    5 mM 0.5020 mL 2.5101 mL 5.0202 mL 12.5505 mL
    10 mM 0.2510 mL 1.2551 mL 2.5101 mL 6.2753 mL
    15 mM 0.1673 mL 0.8367 mL 1.6734 mL 4.1835 mL
    20 mM 0.1255 mL 0.6275 mL 1.2551 mL 3.1376 mL
    25 mM 0.1004 mL 0.5020 mL 1.0040 mL 2.5101 mL
    30 mM 0.0837 mL 0.4184 mL 0.8367 mL 2.0918 mL
    40 mM 0.0628 mL 0.3138 mL 0.6275 mL 1.5688 mL
    50 mM 0.0502 mL 0.2510 mL 0.5020 mL 1.2551 mL
    60 mM 0.0418 mL 0.2092 mL 0.4184 mL 1.0459 mL
    80 mM 0.0314 mL 0.1569 mL 0.3138 mL 0.7844 mL
    100 mM 0.0251 mL 0.1255 mL 0.2510 mL 0.6275 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱(chēng):

     

    * 需求量:

    * 客戶(hù)姓名:

     

    * Email:

    * 電話(huà):

     

    * 公司或機(jī)構(gòu)名稱(chēng):

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱(chēng):
    Sulfasalazine
    目錄號(hào):
    HY-14655
    需求量: